In his weekly clinical update Dr. Griffin discusses a healthcare-associated infection with Monkeypox virus, air and surface sampling for monkeypox virus in a UK hospital, misrepresentation and nonadherence regarding COVID19 public health measures, tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine, clinical, virologic, and immunologic evaluation of symptomatic rebound following Nirmatrelvir/Ritonavir treatment, early outpatient treatment with Eemdesivir in patients at high risk for severe COVID-19, Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes, and outcomes among confirmed cases and a matched comparison group in the long-COVID in Scotland.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Research assistant position with Amy Rosenfeld (pdf)
• Support MicrobeTV with a Spike t-shirt at Vaccinated.US
• A healthcare-associated infection with monkeypox virus (OFID)
• Air and surface sampling for monkeypox virus (The Lancet)
• Misrepresentation & nonadherence in COVID-19 public health measures (JAMA)
• Tolerability and immunogenicity of a COVID-19 vaccine (The Lancet)
• PAXLOVID patient eligibility screening checklist (FDA)
• Evaluation of symptomatic disease rebound following PAXLOVID (CID)
• Outpatient treatment with Remdesivir in patients at high risk (OFID)
• Remdesivir fact sheet for providers (Veklury)
• Bebtelovimab fact sheet for providers (FDA)
• Molnupiravir as early treatment for adults with COVID-19 (SSRN)
• Outcomes among confirmed cases and matched comparison group in long-COVID (Nature)
• Dr. Griffin's treatment guide (pdf)
• Contribute to Floating Doctors fundraiser at PWB
• Letters read on TWiV 945
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]